Novartis, Pear Therapeutics To Market Digital TherapeuticsBy
Sandoz, Novartis’ generics arm, has partnered with Pear Therapeutics, a Boston, Massachusetts-based prescription digital therapeutics company, to commercialize Pear Therapeutics’ two lead products, reSET and reSET-O, digital therapeutics for treating substance abuse.
In addition to an upfront payment, the deal includes research and development funding, commercial milestones, and a profit split on net sales of both therapeutics.
reSET was cleared by the US Food and Drug Administration (FDA) in September 2017 for treating patients with substance-use disorder. reSET-O, a potential prescription digital therapeutic for treating opioid-use disorder, was granted expedited access pathway designation in October 2017 and is currently under review by the FDA.
Sandoz will assume responsibility for the global commercial launch of reSET, and reSET-O (once approved), including ensuring market access, reimbursement from payors, and providing a sales force. Pear will continue to develop both digital therapeutics and will also support patient services through its digital hub service.
Pear’s prescription digital therapeutics aim to be designed to deliver clinically proven treatments, such as cognitive behavioral therapy, to patients through mobile and desktop applications. Once cleared by the FDA, these digital therapeutics may be prescribed as monotherapies or alongside drug therapies and have the potential to be developed to treat a range of diseases, according to information from Novartis.
This collaboration is part of the Sandoz and Novartis strategic effort to work with digital health leaders. Sandoz and Novartis are collaborating to develop technologies to monitor patient data in real-time, detect day-to-day behavioral and biological changes in condition, improve patient adherence, and ultimately enhance treatment outcomes, according to information from Novartis.